TWI826525B - 用於治療特定白血病之化合物 - Google Patents

用於治療特定白血病之化合物 Download PDF

Info

Publication number
TWI826525B
TWI826525B TW108133432A TW108133432A TWI826525B TW I826525 B TWI826525 B TW I826525B TW 108133432 A TW108133432 A TW 108133432A TW 108133432 A TW108133432 A TW 108133432A TW I826525 B TWI826525 B TW I826525B
Authority
TW
Taiwan
Prior art keywords
group
substituted
alkyl
cycloalkyl
compound
Prior art date
Application number
TW108133432A
Other languages
English (en)
Chinese (zh)
Other versions
TW202024037A (zh
Inventor
Ｆ 安東尼 羅梅洛
索爾斯坦 Ａ 科許柏格
朗道爾 海克
英姿 徐
Original Assignee
美商拓臻股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商拓臻股份有限公司 filed Critical 美商拓臻股份有限公司
Publication of TW202024037A publication Critical patent/TW202024037A/zh
Application granted granted Critical
Publication of TWI826525B publication Critical patent/TWI826525B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW108133432A 2018-09-18 2019-09-17 用於治療特定白血病之化合物 TWI826525B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862733029P 2018-09-18 2018-09-18
US62/733,029 2018-09-18
US201962816637P 2019-03-11 2019-03-11
US62/816,637 2019-03-11
US201962889929P 2019-08-21 2019-08-21
US62/889,929 2019-08-21

Publications (2)

Publication Number Publication Date
TW202024037A TW202024037A (zh) 2020-07-01
TWI826525B true TWI826525B (zh) 2023-12-21

Family

ID=69774840

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108133432A TWI826525B (zh) 2018-09-18 2019-09-17 用於治療特定白血病之化合物

Country Status (19)

Country Link
US (4) US10889571B2 (enExample)
EP (1) EP3852745A4 (enExample)
JP (2) JP7611832B2 (enExample)
KR (2) KR20210061377A (enExample)
CN (3) CN115448908B (enExample)
AU (2) AU2019342102C1 (enExample)
BR (1) BR112021004051A2 (enExample)
CA (1) CA3110576A1 (enExample)
CL (1) CL2021000637A1 (enExample)
CO (1) CO2021004704A2 (enExample)
IL (2) IL281427B2 (enExample)
MA (1) MA53664A (enExample)
MX (2) MX2021003093A (enExample)
NZ (1) NZ773110A (enExample)
PE (2) PE20211644A1 (enExample)
SG (1) SG11202102367TA (enExample)
TW (1) TWI826525B (enExample)
WO (1) WO2020061086A2 (enExample)
ZA (1) ZA202101304B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ773110A (en) 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
BR112021017756A2 (pt) 2019-03-11 2021-11-16 Inflarx Gmbh Piperidinila bicíclica fundida e compostos relacionados como moduladores do receptor c5a
EP3947369A4 (en) * 2019-07-29 2022-10-05 Ascentage Pharma (Suzhou) Co., Ltd. HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
JP2024510935A (ja) * 2021-03-03 2024-03-12 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
CN116375650B (zh) * 2022-12-30 2025-08-05 浙江美诺华药物化学有限公司 一种替戈拉生中间体的制备方法
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
TW202525293A (zh) 2023-08-31 2025-07-01 美商拓臻製藥公司 用於治療癌症之組合
WO2025226724A1 (en) 2024-04-23 2025-10-30 Terns Pharmaceuticals, Inc. Bcr-abl1 inhibitors for use in treating cancer
CN120842151A (zh) * 2024-04-26 2025-10-28 北京英飞智药科技有限公司 一种2-芳基苯并咪唑类化合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200829563A (en) * 2006-10-18 2008-07-16 Novartis Ag Organic compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00011470A (es) 1998-05-22 2002-10-17 Avanir Pharmaceuticals Analogos de bencimidazol como reguladores de la disminucion de ige.
SE0003476D0 (sv) 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
AR053364A1 (es) * 2005-04-20 2007-05-02 Smithkline Beecham Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
CN101553468A (zh) * 2006-10-18 2009-10-07 诺瓦提斯公司 有机化合物
GB0800035D0 (en) 2008-01-02 2008-02-13 Glaxo Group Ltd Compounds
WO2013033093A1 (en) 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
ES2670601T3 (es) 2012-05-15 2018-05-31 Novartis Ag Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
KR20150008406A (ko) 2012-05-15 2015-01-22 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
MX357305B (es) 2012-05-15 2018-07-04 Novartis Ag Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
CN103113355B (zh) 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用
GB201401086D0 (en) 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
CN109790144A (zh) 2016-04-29 2019-05-21 爱仕达生物技术有限责任公司 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂
JP6778833B2 (ja) 2017-01-20 2020-11-04 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． キナーゼ活性を抑制するための（ヘテロ）アリールアミド類化合物
CN108602800B (zh) 2017-01-20 2019-08-27 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
WO2018191146A1 (en) * 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
US11649218B2 (en) 2018-03-09 2023-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
NZ773110A (en) 2018-09-18 2024-11-29 Terns Inc Compounds for treating certain leukemias
US20240262842A1 (en) 2021-04-27 2024-08-08 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12c mutant
KR20240089224A (ko) 2021-09-30 2024-06-20 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 4-원 융합 고리형 화합물 및 이의 제조방법 및 용도
TW202502333A (zh) 2023-03-30 2025-01-16 大陸商江蘇豪森藥業集團有限公司 四元稠環類化合物鹽晶型及其製備方法和應用
TW202525293A (zh) 2023-08-31 2025-07-01 美商拓臻製藥公司 用於治療癌症之組合

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200829563A (en) * 2006-10-18 2008-07-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP7611832B2 (ja) 2025-01-10
IL281427A (en) 2021-04-29
WO2020061086A2 (en) 2020-03-26
MX2021003093A (es) 2021-05-12
IL322515A (en) 2025-10-01
AU2019342102B2 (en) 2024-10-03
US20250243184A1 (en) 2025-07-31
CN115215838A (zh) 2022-10-21
MX2023007714A (es) 2023-07-10
JP2025066704A (ja) 2025-04-23
MA53664A (fr) 2022-05-04
CN115448908A (zh) 2022-12-09
CL2021000637A1 (es) 2021-10-01
ZA202101304B (en) 2024-09-25
PE20211644A1 (es) 2021-08-24
IL281427B1 (en) 2025-09-01
NZ773110A (en) 2024-11-29
CN112770745B (zh) 2022-09-02
BR112021004051A2 (pt) 2021-05-25
US12240835B2 (en) 2025-03-04
US10889571B2 (en) 2021-01-12
US12454524B2 (en) 2025-10-28
CN115448908B (zh) 2025-04-25
CN115215838B (zh) 2025-04-04
CO2021004704A2 (es) 2021-04-30
KR20210061377A (ko) 2021-05-27
WO2020061086A3 (en) 2020-07-23
US20200087283A1 (en) 2020-03-19
KR20260019669A (ko) 2026-02-10
US20250276961A1 (en) 2025-09-04
IL281427B2 (en) 2026-01-01
PE20252740A1 (es) 2025-12-05
AU2019342102C1 (en) 2026-02-19
TW202024037A (zh) 2020-07-01
JP2022501429A (ja) 2022-01-06
AU2019342102A1 (en) 2021-03-11
SG11202102367TA (en) 2021-04-29
EP3852745A2 (en) 2021-07-28
AU2024287115A1 (en) 2025-01-16
CN112770745A (zh) 2021-05-07
US20240101536A1 (en) 2024-03-28
CA3110576A1 (en) 2020-03-26
EP3852745A4 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
US12240835B2 (en) Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity
AU2020343671B2 (en) RIP1 inhibitory compounds and methods for making and using the same
JP7846735B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
KR20240069725A (ko) 피리딘 유도체 및 이의 용도
CN114430743A (zh) 甲状腺激素受体β激动剂化合物
JP2016537366A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
ES2984158T3 (es) Inhibidores y moduladores de WDR5
US20250144094A1 (en) Thiophene ulk1/2 inhibitors and their use thereof
RU2804709C9 (ru) Соединения для лечения некоторых лейкозов
RU2804709C2 (ru) Соединения для лечения некоторых лейкозов
TW202543630A (zh) 作為ｔｅａｄ抑制劑的螺環化合物
BR122025027049A2 (pt) Compostos, sal de adição de ácido farmaceuticamente aceitável, seu método de produção e métodos de síntese de compostos
HK40052099B (en) Compounds for treating certain leukemias
HK40052099A (en) Compounds for treating certain leukemias
WO2025170939A1 (en) Proteasome inhibitors for the treatment of malaria
NZ623098A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.